Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab added to standard care for acute antibody-mediated kidney transplant rejection
ISRCTN18179652Phase 3Terminated
- Sponsor
- Imperial College London
- Start
- Feb 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial in antibody mediated rejection (AMR) comparing Standard of care with Standard of care plus rituximab (2 arms). Primary endpoint: Allograft survival. Started Feb 2019; status: terminated.
02
Drugs
rituximab
03
Conditions
antibody mediated rejection (AMR)
Beyond the preview
Go deeper on ISRCTN18179652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN18179652.